Investor relations
NÖK Therapeutics, Inc. OTC: NKTP
Company information, public disclosures and resources for shareholders of NÖK Therapeutics, Inc., a clinical-stage biotechnology company developing autologous natural killer (NK) cell therapies for cancer.
- Symbol
- NKTP
- Market
- OTCID Basic Market (OTC Markets Group)
- SEC CIK
- 0002038166
- Fiscal year-end
- December 31
Investor resources
As a publicly quoted company, NÖK is committed to clear, timely communication with shareholders, prospective investors and the wider investment community. Everything we publish for investors is here.
- 01Stock informationTrading symbol, market, transfer agent and quotes.
- 02SEC filingsAnnual, semiannual and current reports, from EDGAR.
- 03Press releasesOfficial company announcements, newest first.
- 04Corporate governanceBoard of Directors, leadership and adopted policies.
- 05Investor contactInvestor relations and shareholder services.
- 06Legal & disclosuresForward-looking statements and website notices.
Latest SEC filings
- September 28, 2026Form 1-SA Semiannual report, period ended June 30, 2026
- July 15, 2026Form 1-U Current report
- June 3, 2026Form 1-U Current report
- April 30, 2026Form 1-K Annual report, fiscal year ended December 31, 2025
Latest press releases
No press releases yet. Official announcements will appear here as they are issued.
Investing in biotechnology companies involves substantial risks, including risks associated with research and development, regulatory approval, financing and commercialization. Investors should review the company'sSEC filings and the risk disclosures in them before making investment decisions. Nothing on this website is an offer to sell, or a solicitation of an offer to buy, any securities, or investment advice. See our legal disclosures and forward-looking statements.